Regeneron Reports Second Quarter 2018 Financial and Operating Results

TARRYTOWN, N.Y.,Aug. 2, 2018/PRNewswire/ --

• Second quarter 2018 GAAP net income per diluted share increased by 44% to$4.82versus second quarter 2017 and second quarter 2018 non-GAAP net income per diluted share increased 31% to$5.45versus second quarter 2017

• Second quarter 2018 EYLEA®(aflibercept) Injection U.S. net sales increased 8% to$992 millionversus second quarter 2017 and second quarter 2018 EYLEA global net sales(1)increased 13% to$1.66 billionversus second quarter 2017

• Positive results reported from Phase 3 trial of Dupixent®(dupilumab) in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial results for the second quarter of 2018 and provided a business update.

"Regeneron made important commercial progress in the second quarter with continued strong U.S. sales growth for EYLEA in retinal diseases and Dupixent in atopic dermatitis.  We are particularly pleased by U.S. launch progress with Dupixent for adults with moderate-to-severe atopic dermatitis, driven by a positive experience in the marketplace by patients and physicians in this serious disease; we anticipate continued robust growth as more physicians increase their experience with the product," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "In the second half of the year, we anticipate two significant U.S. regulatory approvals: cemiplimab for advanced cutaneous squamous cell carcinoma and Dupixent for uncontrolled asthma.  We also plan to submit regulatory applications for Dupixent in adolescent atopic dermatitis and to report Phase 3 results in nasal polyps, in addition to other advances across our innovative portfolio for serious diseases."

($ in millions, except per share data)

Total revenues

$

1,608

$

1,470

9

%

GAAP net income

$

551

$

388

42

%

GAAP net income per share - diluted

$

4.82

$

3.34

44

%

Non-GAAP net income(2)

$

624

$

487

28

%

Non-GAAP net income per share - diluted(2)

$

5.45

$

4.17

31

%

($ in millions)

EYLEA*

$

992

$

666

$

1,658

$

919

$

542

$

1,461

8%

23%

13%

ARCALYST

4

—

4

5

—

5

(20)%

—

(20%)

Net product salesrecorded byRegeneron

$

996

$

924

8%

Net product sales recorded by Sanofi*:

Dupixent

$

181

$

28

$

209

$

28

—

$

28

546%

Praluent

42

32

74

33

$

13

46

27%

146%

61%

Kevzara

19

5

24

1

—

1

ZALTRAP

3

25

28

2

18

20

50%

39%

40%

* Bayer records net product sales of EYLEA outside the United States and Sanofi records global net product sales of Dupixent, Praluent, Kevzara, and ZALTRAP.  Refer to Table 4 below for the Company's share of profits/losses recorded in connection with sales of EYLEA outside the United States and global sales of Dupixent, Praluent, and Kevzara.  Sanofi pays the Company a percentage of aggregate net sales of ZALTRAP.

** Percentage not meaningful

Key Pipeline ProgressRegeneron has nineteen product candidates in clinical development, which consist of EYLEA and fully human antibodies generated using the Company'sVelocImmune®technology, including eight in collaboration with Sanofi.  Updates from the clinical pipeline include:

EYLEA®(aflibercept) Injection

• The Company recently submitted a supplemental Biologics License Application (sBLA) for EYLEA for the treatment of diabetic retinopathy.

• In the second quarter of 2018, the Company submitted an sBLA for EYLEA in a pre-filled syringe.

Dupixent®(dupilumab) Injection

• Dupixent, an antibody that blocks signaling of IL-4 and IL-13, is being studied in asthma, adolescent and pediatric atopic dermatitis, nasal polyps, eosinophilic esophagitis (EoE), and grass immunotherapy, with additional studies planned in 2018.

• InMay 2018, the Company and Sanofi reported that a Phase 3 trial evaluating Dupixent to treat moderate-to-severe atopic dermatitis in adolescents (12–17 years of age) met its primary and key secondary endpoints.

• InMay 2018, the Company and Sanofi announced that theNew England Journal of Medicinepublished detailed, positive results from two Phase 3 trials of Dupixent in moderate-to-severe asthma.

• In the second quarter of 2018, a Phase 2 study of Dupixent in grass immunotherapy was initiated.

Praluent®(alirocumab) Injection

• InMay 2018, the Company and Sanofi announced they will lower the net price of Praluent in exchange for straightforward, more affordable patient access from Express Scripts. Praluent has been chosen as the exclusive PCSK9 inhibitor therapy on the Express Scripts national formulary. The agreement took effect onJuly 1, 2018.

• An sBLA and a Marketing Authorization Application (MAA) for Praluent for cardiovascular risk reduction have been recently submitted.

• An sBLA for first-line treatment of hyperlipidemia has also been recently submitted.

• In the second quarter of 2018, a Phase 3 pediatric study in heterozygous familial hypercholesterolemia (HeFH) was initiated.

Cemiplimab, an antibody to PD-1, is being studied in patients with cancer.

• InApril 2018, the FDA accepted for priority review the BLA for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery. The target action date for the FDA decision isOctober 28, 2018.

• InApril 2018, the European Medicines Agency (EMA) also accepted for review the MAA for cemiplimab in patients with metastatic CSCC or patients with locally advanced CSCC who are not candidates for surgery.

• InJune 2018, the Company and Sanofi announced that pivotal data from two trials evaluating cemiplimab in advanced CSCC were published in theNew England Journal of Medicine.

• InMay 2018, the Company and Sanofi announced positive interim results from a Phase 1 study assessing cemiplimab as a potential treatment for advanced non-small cell lung cancer (NSCLC).

Fasinumab, an antibody targeting Nerve Growth Factor (NGF), is being studied in patients with osteoarthritis of the knee or hip.

• InApril 2018, an independent Data Monitoring Committee monitoring the ongoing safety and efficacy of the fasinumab clinical trials recommended that the higher dose-regimens be discontinued based on the risk benefit assessment and that the program may continue with the lower dose-regimens of fasinumab; the ongoing osteoarthritis trials have been modified accordingly. Since the Phase 3 clinical study in chronic low back pain in patients with concomitant osteoarthritis was only using higher doses, the Company is no longer actively dosing patients in this study.

Evinacumabis an antibody to ANGPTL3.  In the second quarter of 2018, a Phase 3 study in severe hypertriglyceridemia was initiated.

REGN3500is an antibody to IL-33.  In the third quarter of 2018, a Phase 2 study in chronic obstructive pulmonary disease (COPD) was initiated.

REGN3918(pozelimab) is an antibody to C5.  The Company expects to report full data from its Phase 1 study in paroxysmal nocturnal hemoglobinuria (PNH) in the second half of 2018, and plans to initiate a Phase 2 study in PNH in early 2019.

REGN4018is a bi-specific antibody targeting MUC16 and CD3.  In the second quarter of 2018, a Phase 1 study in platinum-resistant ovarian cancer was initiated.

REGN4659is an antibody against CTLA4.  In the second quarter of 2018, a Phase 1 study in advanced NSCLC was initiated.

EYLEA

-- FDA decision on sBLA for every 12-week dosing interval in wet AMD (target action date of August 11, 2018)-- Report one-year data from Phase 3 PANORAMA study for the treatment of non-proliferative diabetic retinopathy in patients without diabetic macular edema (DME)

Dupixent (dupilumab)

-- FDA decision on sBLA for asthma in adult/adolescent patients (target action date of October 20, 2018)-- Additional regulatory agency decisions on applications for atopic dermatitis in adults outside the United States-- Submit sBLA and MAA for expanded indication in adolescent patients with atopic dermatitis (12–17 years of age)-- Report data from Phase 3 studies in nasal polyps-- Initiate Phase 3 study in EoE-- Initiate Phase 2 study in peanut allergy

Praluent (alirocumab)

-- FDA decision on sBLA for use with apheresis (target action date of August 24, 2018)--Initiate Phase 3 pediatric study in homozygous familial hypercholesterolemia (HoFH)

Kevzara (sarilumab)

-- Initiate Phase 3 study in giant cell arteritis-- Initiate Phase 3 study in polymyalgia rheumatica

Cemiplimab (PD-1 Antibody)

-- FDA decision on BLA for advanced CSCC (target action date of October 28, 2018)-- Continue Phase 3 patient enrollment for the treatment of non-small cell lung cancer, as well as various other studies

Fasinumab (NGF Antibody)

-- Report data from first Phase 3 efficacy study in osteoarthritis pain-- Continue patient enrollment in Phase 3 long-term safety and efficacy studies in osteoarthritis

REGN3500 (IL-33 Antibody)

-- Initiate Phase 2 study in atopic dermatitis

Bispecific Antibodies

-- Initiate Phase 2 study for REGN1979 (CD20xCD3 Antibody) in follicular lymphoma-- Submit Investigational New Drug Application (IND) for BCMAxCD3 antibody

Product Revenues:Net product sales were$996 millionin the second quarter of 2018, compared to$924 millionin the second quarter of 2017.  EYLEA net product sales inthe United Stateswere$992 millionin the second quarter of 2018, compared to$919 millionin the second quarter of 2017.  Overall distributor inventory levels remained within the Company's one- to two-week targeted range.

Total Revenues:Total revenues, which include product revenues described above, increased by 9% to$1.608 billionin the second quarter of 2018, compared to$1.470 billionin the second quarter of 2017.  Total revenues include Sanofi and Bayer collaboration revenues of$501 millionin the second quarter of 2018, compared to$432 millionin the second quarter of 2017.  Sanofi collaboration revenue in the second quarter of 2018 increased primarily due to the Company's share of higher net sales of Dupixent and an increase in reimbursable expenses in connection with late-stage clinical development activities for cemiplimab.  These increases were partly offset by the Company's Discovery and Preclinical Development Agreement with Sanofi ending onDecember 31, 2017, lower reimbursement for Dupixent development activities, and an increase in the Company's share of the collaboration's Dupixent commercialization expenses.  Bayer collaboration revenue increased in the second quarter of 2018 primarily due to an increase in the Company's share of net profits in connection with higher sales of EYLEA outsidethe United States.

The Company adopted Accounting Standard Codification (ASC) 606,Revenue from Contracts with Customers, as ofJanuary 1, 2018.  The Company adopted the standard using the modified retrospective method; prior period amounts have not been adjusted and the adoption of the new standard did not have a material impact on the Company's total revenues in the second quarter of 2018.

Refer to Table 4 for a summary of collaboration and other revenue.

Research and Development (R&D) Expenses:GAAP R&D expenses were$529 millionin the second quarter of 2018, compared to$510 millionin the second quarter of 2017.  The higher R&D expenses in the second quarter of 2018 were principally due to an increase in cemiplimab and fasinumab clinical trial costs and higher R&D headcount and facilities-related costs, partly offset by a decrease in Dupixent development expenses and the discontinuation of certain development programs.  In the second quarter of 2018, R&D-related non-cash share-based compensation expense was$60 million, compared to$70 millionin the second quarter of 2017.

Selling, General, and Administrative (SG&A) Expenses:GAAP SG&A expenses were$365 millionin the second quarter of 2018, compared to$307 millionin the second quarter of 2017.  The higher SG&A expenses in the second quarter of 2018 were primarily due to higher headcount and headcount-related costs and an increase in commercialization-related expenses for EYLEA and Dupixent, and, to a lesser extent, for cemiplimab.  In the second quarter of 2018, SG&A-related non-cash share-based compensation expense decreased to$40 million, compared to$45 millionin the second quarter of 2017.

Income Tax Expense:In the second quarter of 2018, GAAP income tax expense was$105 millionand the effective tax rate was 16.0%, compared to$138 millionand 26.3% in the second quarter of 2017.  The Company's effective tax rate for the second quarter of 2018 was significantly impacted by the bill known as the Tax Cuts and Jobs Act (the "U.S. Tax Reform Act"), which reduced the U.S. federal corporate income tax rate from 35% to 21% effectiveJanuary 1, 2018.  The effective tax rate for the second quarter of 2018 was positively impacted, compared to the U.S. federal statutory rate, primarily by the tax benefit associated with stock-based compensation, income earned in foreign jurisdictions with tax rates lower than the U.S. federal statutory rate, the foreign-derived intangible income deduction, and the federal tax credit for research activities.

Other income (expense), net:GAAP other income in the second quarter of 2018 included the recognition of$17 millionof net unrealized gains on equity securities.  In the first quarter of 2018, the Company adopted Accounting Standards Update ("ASU") 2016-01,Recognition and Measurement of Financial Assets and Financial Liabilities, as ofJanuary 1, 2018, which requires the Company to measure equity investments at fair value with changes in fair value recognized in net income; previously, such changes in fair value were recognized in Other comprehensive income (loss).  Refer to Table 3 for the non-GAAP adjustment related to gains and losses on investments in equity securities.

GAAP other expenses in the second quarter of 2017 included a$30 millionloss on debt extinguishment related to the 2017 Tarrytown lease transaction.

GAAP and Non-GAAP Net Income(2):GAAP net income was$551 million, or$5.12per basic share and$4.82per diluted share, in the second quarter of 2018, compared to GAAP net income of$388 million, or$3.66per basic share and$3.34per diluted share, in the second quarter of 2017.

Non-GAAP net income was$624 million, or$5.79per basic share and$5.45per diluted share, in the second quarter of 2018, compared to non-GAAP net income of$487 million, or$4.59per basic share and$4.17per diluted share, in the second quarter of 2017.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

The Company's updated full year 2018 financial guidance consists of the following components:

Sanofi collaboration revenue: Sanofireimbursement of Regeneroncommercialization-related expenses

$455 million–$485 million

(previously $450 million–$485 million)

Non-GAAP unreimbursed R&D(2)(4)

$1.210 billion–$1.260 billion

(previously $1.230 billion–$1.310 billion)

Non-GAAP SG&A(2)(4)

$1.340 billion–$1.390 billion

(previously $1.325 billion–$1.395 billion)

Effective tax rate

13%–16%

(previously 15%–18%)

Capital expenditures

$410 million–$450 million

(previously $420 million–$480 million)

(1)

Regeneron records net product sales of EYLEA in the United States.  Outside the United States, EYLEA net product sales comprise sales by Bayer in countries other than Japan and sales by Santen Pharmaceutical Co., Ltd. in Japan under a co-promotion agreement with an affiliate of Bayer.  The Company recognizes its share of the profits (including a percentage on sales in Japan) from EYLEA sales outside the United States within "Bayer collaboration revenue" in its Statements of Operations.

(2)

This press release uses non-GAAP net income, non-GAAP net income per share, non-GAAP unreimbursed R&D, and non-GAAP SG&A, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles ("GAAP").  These non-GAAP financial measures are computed by excluding certain non-cash and other items from the related GAAP financial measure.  Non-GAAP adjustments also include the estimated income tax effect of reconciling items.

The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance.  For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's equity investments) or items that are not associated with normal, recurring operations (such as changes in applicable laws and regulations).  Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis.  Additionally, such non-GAAP measures provide investors with an enhanced understanding of the financial performance of the Company's core business operations.  However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature.  Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies.  Any non-GAAP financial measure presented by Regeneron should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.  A reconciliation of the Company's historical GAAP to non-GAAP results is included in Table 3 of this press release.

(3)

The Company's 2018 financial guidance does not assume the completion of any significant business development transactions not completed as of the date of this press release.

(4)

A reconciliation of full year 2018 non-GAAP to GAAP financial guidance is included below:

GAAP unreimbursed R&D(5)

$

1,425

$

1,495

R&D: Non-cash share-based compensation expense

(215)

(235)

Non-GAAP unreimbursed R&D

$

1,210

$

1,260

GAAP SG&A

$

1,505

$

1,585

SG&A: Non-cash share-based compensation expense

(165)

(195)

Non-GAAP SG&A

$

1,340

$

1,390

(5)

Unreimbursed R&D represents R&D expenses reduced by R&D expense reimbursements from the Company's collaborators and/or customers.

Regeneron will host a conference call and simultaneous webcast to discuss its second quarter 2018 financial and operating results on Thursday, August 2, 2018, at8:30 AM.  To access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International).  A link to the webcast may be accessed from the "Investors and Media" page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.  Founded and led for 30 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in Regeneron's laboratories.  Regeneron's medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases, and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through its proprietaryVelociSuite®technologies, such asVelocImmune®which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the Company, please visitwww.regeneron.comor follow @Regeneron on Twitter.

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; the likelihood and timing of achieving any of the anticipated milestones described in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab) Injection, Praluent®(alirocumab) Injection, Kevzara®(sarilumab) Injection, cemiplimab, fasinumab, and evinacumab; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as EYLEA, Dupixent, Praluent, and Kevzara), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including without limitation those relating to Sanofi reimbursement of Regeneron commercialization-related expenses, non-GAAP unreimbursed R&D, non-GAAP SG&A, effective tax rate, and capital expenditures; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to EYLEA, Dupixent, and Praluent, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition.  A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission.  Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

This press release and/or the financial results attached to this press release include amounts that are considered "non-GAAP financial measures" under SEC rules.  As required, Regeneron has provided reconciliations of historical non-GAAP financial measures.

TABLE 1

Assets:

Cash and marketable securities

$

3,728,221

$

2,896,074

Accounts receivable - trade, net

1,534,324

1,538,642

Accounts receivable from Sanofi and Bayer

504,923

435,698

Inventories

928,553

726,138

Property, plant, and equipment, net

2,461,614

2,358,605

Deferred tax assets

545,077

506,291

Other assets

249,268

302,838

Total assets

$

9,951,980

$

8,764,286

Liabilities and stockholders' equity:

Accounts payable, accrued expenses, and other liabilities

$

1,032,635

$

967,418

Deferred revenue

1,027,016

949,337

Capital and facility lease obligations

705,903

703,453

Stockholders' equity

7,186,426

6,144,078

Total liabilities and stockholders' equity

$

9,951,980

$

8,764,286

TABLE 2

Revenues:

Net product sales

$

996,382

$

924,133

$

1,984,291

$

1,782,378

Sanofi collaboration revenue

237,753

222,128

427,243

432,495

Bayer collaboration revenue

262,863

210,355

510,791

404,294

Other revenue

111,024

113,500

197,182

169,940

1,608,022

1,470,116

3,119,507

2,789,107

Expenses:

Research and development

529,289

509,975

1,027,875

1,017,410

Selling, general, and administrative

364,884

306,908

695,654

603,754

Cost of goods sold

35,950

42,133

105,193

103,386

Cost of collaboration and contract manufacturing

55,711

60,788

101,366

83,703

985,834

919,804

1,930,088

1,808,253

Income from operations

622,188

550,312

1,189,419

980,854

Other income (expense), net

33,886

(24,462)

52,053

(22,715)

Income before income taxes

656,074

525,850

1,241,472

958,139

Income tax expense

(104,662)

(138,106)

(212,080)

(321,464)

Net income

$

551,412

$

387,744

$

1,029,392

$

636,675

Net income per share - basic

$

5.12

$

3.66

$

9.56

$

6.02

Net income per share - diluted

$

4.82

$

3.34

$

8.97

$

5.51

Weighted average shares outstanding - basic

107,800

106,034

107,724

105,804

Weighted average shares outstanding - diluted

114,477

116,137

114,697

115,607

TABLE 3

GAAP net income

$

551,412

$

387,744

$

1,029,392

$

636,675

Adjustments:

R&D: Non-cash share-based compensationexpense

59,602

69,528

100,437

143,051

SG&A: Non-cash share-based compensationexpense

40,467

44,708

75,481

98,520

COGS and COCM: Non-cash share-basedcompensation expense

6,726

7,022

13,299

13,476

Other expense: Loss on extinguishment of debt

—

30,100

—

30,100

Other income/expense: Gains and losses oninvestments in equity securities(a)

(16,520)

—

(25,889)

—

Income tax effect of reconciling items above

(18,035)

(52,310)

(32,336)

(98,500)

Non-GAAP net income

$

623,652

$

486,792

$

1,160,384

$

823,322

Non-GAAP net income per share - basic

$

5.79

$

4.59

$

10.77

$

7.78

Non-GAAP net income per share - diluted

$

5.45

$

4.17

$

10.12

$

7.10

Shares used in calculating:

Non-GAAP net income per share - basic

107,800

106,034

107,724

105,804

Non-GAAP net income per share - diluted

114,478

116,832

114,700

115,903

(a)Prior to the quarter ended March 31, 2018, unrealized gains and losses on equity securities were recorded in Other comprehensive income (loss).  In connection with the adoption of ASU 2016-01, unrealized gains and losses on equity securities during the three and six months ended June 30, 2018 were recorded in Other income, net.

TABLE 4

Sanofi collaboration revenue:

Reimbursement of Regeneron research anddevelopment expenses

$

141,536

$

205,352

$

275,754

$

419,276

Reimbursement of Regeneron commercialization-related expenses

105,727

87,853

192,361

161,412

Regeneron's share of losses in connection withcommercialization of antibodies

(68,797)

(122,281)

(143,671)

(230,683)

Other

59,287

51,204

102,799

82,490

Total Sanofi collaboration revenue

237,753

222,128

427,243

432,495

Bayer collaboration revenue:

Regeneron's net profit in connection withcommercialization of EYLEA outside theUnited States

246,302

190,883

478,370

365,759

Reimbursement of Regeneron developmentexpenses

3,867

6,720

7,864

13,069

Other

12,694

12,752

24,557

25,466

Total Bayer collaboration revenue

262,863

210,355

510,791

404,294

Total Sanofi and Bayer collaboration revenue

$

500,616

$

432,483

$

938,034

$

836,789

Other revenue:

Reimbursement of Regeneron research anddevelopment expenses - Teva

$

34,310

$

31,481

$

73,439

$

53,531

Reimbursement of Regeneron research anddevelopment expenses - other

3,889

762

6,584

3,412

Other

72,825

81,257

117,159

112,997

Total other revenue

$

111,024

$

113,500

$

197,182

$

169,940